Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
26 Feb, 26
ADA 2026 outlines the standards for obesity pharmacotherapy. It recommends combining person-centered medication with lifestyle changes for adults with obesity. It details weight-loss targets and drug benefits for comorbidities
23 Feb, 26
The updated international urticaria guideline describes its definition, classification and recommendations for diagnosing and managing its various subtypes.
4 Mar, 26
BMJ Open Res Clin.
- As per the analysis of 2016–2021 NIS data of adults with T1DM hospitalized for DKA, sex–age interactions influenced outcomes
- Women had lower AKI odds (aOR 0.56, 0.71, 0.79 across age groups) but higher sepsis odds (aOR 1.66, 1.31, 1.17; all p<0.05)
- Mortality benefit for women was limited to ages 18–44 (aOR 0.72)
- COVID-19 years saw mortality rise across all groups, most in young men (from 0.48% to 0.89%)
2 Mar, 26Eur Urol
- This randomized study showed that biparametric MRI‑first screening, regardless of PSA levels increased biopsy (10.8% vs 5.2%) and csPCa detection (4.6% vs 1.8%) as compared to those who received bpMRI only if PSA >3 ng/ml
- Benefit–harm metrics favored MRI first, with higher grade selectivity, biopsy efficiency, and biopsy avoidance
- The strategy was cost effective with no serious adverse events.
26 Feb, 26Diabetes Metab Syndr...
- In 789 Indian T2DM+MASLD patients (mean age 53.3 yrs), LSM ≥9.7 in 12.9%
- FIB 4 rule in cut off: 1.68 (AUROC 0.69, sens 64.7%, spec 65.2); NFS −0.389 (AUROC 0.619, sens 61.8%, spec 57.4)
- Rule out AUROCs poor (FIB 4 0.586, NFS 0.570), conventional cut offs had low sensitivity (~21%) but high specificity (~90%)
- Overall, FIB 4/NFS poorly predicted advanced fibrosis in Indian T2DM+MASLD patients.
26 Feb, 26Hypertension.
- Phase III RCT compared low dose telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg vs telmisartan 40 mg in essential HTN patients (n=314)
- At 8 wks, combination reduced SBP more than monotherapy (LS mean diff −3.8 mmHg PPS, FAS −4.0 mmHg), DBP, normalization, & response rates favored combination
- Efficacy was consistent across clinical strata, including age & prior HTN treatment, with comparable safety profile.
The speaker highlighted Secukinumab’s expanding role in psoriasis care, emphasizing its strong data on clear-skin outcomes, sustained efficacy, favorable safety, and robust benefits in managing psoriatic comorbidities including PsA.
Featured
6 Mar, 26
4 Mar, 26
24 Feb, 26
